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Summary
Objectives The identiﬁcation of hyperamylasaemia insufﬁcient to
conﬁdently diagnose acute pancreatitis in patients with epigastric pain
poses a clinical dilemma. The aim of this study was to identify a cohort of
such patients and review their presentation, investigation and outcome.
Design Patients admittedthrough the emergencysurgical intake during
a 12-month period with serum amylase levels of 100–400 IU/L were
identiﬁed and case notes reviewed to conﬁrm those presenting with upper
abdominal pain. Subsequent radiological and biochemical investigations
were recorded.
Participants A total of 25 patients with non-diagnostic
hyperamylasaemia.
Setting Ward patients in a University Hospital.
Main outcome measures Amylase level, eventual diagnosis, drug
history.
Results Twenty-ﬁve patients were identiﬁed with a mean age of 46.7
years. The medianserum amylase levelwas230 IU/L (range 102–358 IU/L).
Twenty-twopatientsunderwenttransabdominalultrasoundatpresentation,
with gallstones identiﬁed in nine cases. The remaining three had
documented gallstones and were awaiting elective cholecystectomy. Of the
13 patients with no evidence of cholelithiasis, six were taking medications
known to cause pancreatitis, seven patients underwent computed
tomography(CT)scansthatidentiﬁedchronicpancreatitisinthree,andwere
non-diagnostic in four cases. These four patients underwent endoscopic
ultrasound (EUS) evaluation of the biliary tree identifying microlithiasis in
one but no pathology in the remaining three cases.
Conclusions Patients with hyperamylasaemia not diagnostic of
pancreatitis should be carefully investigated, as gallstones will be identiﬁed
in at least 50%. An accurate drug history is also invaluable.
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RESEARCH
1Introduction
Acute pancreatitis is deﬁned as an acute inﬂam-
matory process of the pancreas with variable
involvement of regional tissues, or remote organ
systems, associated with raised pancreatic
enzymes levels in the blood or urine.
1 There is
no agreement in the literature as to the exact
serum amylase level required for a diagnosis of
acute pancreatitis. Bollen et al. evaluated the
deﬁnitions of acute pancreatitis in 148 studies, all
of which concluded that a diagnosis of pan-
creatitis should include a characteristic clinical
history of abdominal pain and elevated pan-
creatic enzyme levels.
2 However, the enzyme
levels required to complement the clinical
history ranged from 2–5 times the upper limit of
normal. The guidelines currently used for the
management of acute pancreatitis in the United
Kingdom recommend a threshold of four times
the upper limit of normal, which equates to 400
IU/L.
3 While the British Society of Gastroenterol-
ogy (BSG) guidelines do state that patients with
lesser degrees of elevation in serum amylase and
abdominal pain should be investigated as per
acute pancreatitis, on a practical level, this is not
widely appreciated and hence the guidelines not
always followed.
Identiﬁcation of hyperamylasaemia insufﬁcient
to afford a diagnosis of acute pancreatitis, poses a
clinical dilemma. Is this acute pancreatitis that
has presented very early or possibly late in the
course of the disease thus missing the diagnostic
peak, or is there another cause for the hyperamy-
lasaemia? It is imperative to obtain an accurate
history as to the onset, duration, severity and
nature of the pain so as to determine whether
the patient is likely to be suffering from acute
pancreatitis. It is clearly necessary to determine
whether there is a history of gallstone disease
or of signiﬁcant alcohol consumption, as these
represent the commonest aetiologies of acute
pancreatitis. It is also important to consider
medications that may induce pancreatic injury
and also family histories of acute pancreatitis.
If the history is not consistent with acute pan-
creatitis, then a number of differential diagnoses
must also be considered, all of which have associ-
ated abdominal signs and symptoms (Table 1).
4
The aim of this study was to identify acohort of
patients with hyperamylasaemia together with
appropriate clinical features and to determine
the aetiology of their elevated amylase.
Materials and Methods
All patients admitted on the surgical emergency
intake during a 12-month period with a hypera-
mylasemia of 101–400 IU/L (normal range <100
IU/L) were identiﬁed from the biochemistry
department database.
The case-notes of all patients were reviewed,
and those with a history of upper abdominal
pain were identiﬁed and selected as a cohort for
further study. Individuals with hyperamylasae-
mia but no abdominal pain, and those with
lower abdominal pain were excluded, as were
Table 1
Potential aetiologies for hyperamylasaemaia
Pancreaticobiliary Acute pancreatitis
Choledocholithiasis
Chronic pancreatitis
Pancreatic trauma
Post-ERCP
Postoperative
Abdominal
conditions
Appendicitis
Gastroenteritis
Inﬂammatory bowel
disease
Intestinal obstruction
Mesenteric ischaemia
Peptic ulcer disease
Perforated viscera
Postoperative
Radiation
Ruptured aortic aneurysm
Trauma
Female reproductive
tract
Ectopic pregnancy
Ovarian cysts
Salpingitis
Metabolic clearance Cirrhosis
Hepatitis
Renal failure
Miscellaneous Anorexia nervosa
Burns
Cerebral trauma
Ectopic production by
malignancies
Ketoacidosis
Salivary gland disease
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2patients who had an elevated serum amylase in
association with clinically apparent peritonitis.
The interval between onset and presentation of
pain was evaluated, and the severity and evol-
ution of pain were recorded. A detailed assess-
ment of patient medication history was also
made and all drugs known to cause acute pancrea-
titis were identiﬁed by cross-referencing against
the British National Formulary.
The results of all subsequent radiological and
biochemical investigations were obtained from
the relevant clinical data systems, and patient
management as well as follow-up were deter-
mined from the case-notes.
All patients were followed for a period of 5
years following their presentation with
hyperamylasaemia.
Results
Twenty-ﬁve patients (21 men and 4 women) were
identiﬁed with the combination of hyperamyla-
saemia (amylase 100–400 IU/L) and upper
abdominal pain. The mean age of the patients
was 46.7 years (range 31–71 years). The median
amylase of this cohort was 230 IU/L (range 102–
358 IU/L). The median time from initial pain to
presentation was 2.7 days (range 0–5 days).
The investigation of these patients is summar-
ized in Figure 1. Twenty-two patients underwent
transabdominal ultrasound with gallstones ident-
iﬁed in nine cases. The remaining three patients
were known to have gallstones and were awaiting
elective surgery. None of the patients without
evidence of gallstones admitted to a high alcohol
intake, and none had a documented family
history of pancreatic disease.
Of 13 patients with no evidence of cholelithia-
sis, six patients were taking medications that are
known to cause pancreatitis (statins [n=3];
sodium valproate [n= 1]; azathioprine [n=1];
and prednisolone [n= 1]).
The remaining seven patients without evidence
of acute pancreatitis underwent computed tom-
ography (CT) scans that identiﬁed chronic pan-
creatitis in three cases, and in four they were
non-diagnostic. After disclosing the results of the
CTscans to the patients with radiological evidence
of chronic pancreatitis, all three admitted to
signiﬁcant alcohol consumption earlier in their
adult lives. However, none reported having been
admitted with acute pancreatitis on a previous
occasion, and all denied admission elsewhere
with pancreatitis. The four patients with normal
CT scans underwent endoscopic ultrasound
(EUS) to exclude microlithiasis, this being positive
in one instance.
The three patients with no established cause for
the hyperamylasaemia were two women aged 39
and 67 years, and a man aged 53 years. The
amylase levels of the three patients were 231, 275
and 358 IU/L, respectively.
All patients with gallstones, and the patient
with microlithiasis underwent cholecystectomy
as deﬁnitive treatment, and none have had a recur-
rent admission with hyperamylasaemia. Patients
believed to be suffering from drug-induced hyper-
amlylasaemia had their medications changed to
alternative agents, and have not experienced a
recurrent episode of pain/hyperamylasaemia.
None of the three patients without a diagnosis
have re-presented with abdominal pain during
Figure 1
Flow diagram illustrating investigation of
patients with hyperamylasaemia
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3the subsequent 5 years since their index
presentation.
Discussion
The principal ﬁnding of this study is that the
majorityofpatients22/25(88%)withupperabdomi-
nal pain and a hyperamylasaemia have an identiﬁ-
able cause for the elevation in serum amylase.
Furthermore, most of these patients 13/22 (59%)
do in fact have gallstones/microlithiasis as the
underlying aetiology. A signiﬁcant number 6/22
(27%) had hyperamylasaemia as a result of a pre-
scribed medication, and 3/22 (14%) had chronic
pancreatitis diagnosed following investigation.
The value of serum amylase as a marker of
pancreatic disease was ﬁrst proposed by Elman
and colleagues in 1929, and it is the most widely
used diagnostic test for pancreatitis, with the
majority of patients with acute pancreatitis
having elevated serum amylase levels.
5,6 Serum
amylase levels become elevated within 2 to 12
hours of the onset of pain, peaking within 48
hours and then falling back to basal levels.
7 The
median time from onset of pain to presentation
in the current series was 2.7 days, which may
explain why some of the patients had an
amylase level <400 IU/L.
In clinical practice, there is no current consen-
sus as to the cut-off level of amylase diagnostic
of acute pancreatitis. A level of at least three
times the upper limit has been suggested,
although levels from 2–5 times or more the
upper limit have been used in recent studies.
2,8,9
These normal values are based on the distribution
of serum amylase levels within patient popu-
lations and so for a given individual, a serum
amylase level <400 IU/L may still be associated
with a diagnosis of acute pancreatitis. However,
as the majority of patients do not go conﬁrmatory
cross-sectional imaging it is not possible to
conﬁrm this. On a practical level, the data pre-
sented in this study would suggest that patients
with abdominal pain and hyperamylasaemia
should certainly be investigated and treated in
the same manner as patients with acute pancreati-
tis in accordance with the recommendations of the
BSG guidelines.
3
As stated above, it is clear that the value of the
test to clinical practice is dependent on the
diagnostic level selected. It has been shown that
the sensitivity and speciﬁcity of amylase in the
diagnosis of acute pancreatitis are 91.7–100 and
91.6–97.6% when the cut-off level of amylase is
set at the upper limit of normal, however if the
level is set at an arbitrary 1000 IU/L then the sen-
sitivity rises to 100%, while the speciﬁcity goes
down to 60.9%.
10
In only 3/25 (12%) cases in the current series
was no clear aetiology identiﬁed for the hypera-
mylasaeima. Furthermore, if the drug-induced
hyperamylasaemia cases are regarded as a mild
form of pancreatitis then 88% of patients in our
series had a pancreatobiliary aetiology to their
elevated amylase levels. In contrast, in a study of
patients with hyperamylasaemia and non-speciﬁc
symptoms, 78.9% of patients had no pancreatic
pathology identiﬁed and the authors concluded
that the diagnostic yield was poor, questioning
whether such patients warranted investigation.
11
The strengths of this study include an insight
into a patient group that is generally underinvesti-
gated, and a demonstration that an accurate diag-
nosis can be made on the majority of patients.
Weaknesses may include a relatively small
cohort size, and the retrospective design.
It would appear therefore that a sound history
of upper abdominal pain is present especially if
there is a signiﬁcant interval from onset to presen-
tation then there is likely to be an aetiology
deﬁned by following an acute pancreatitis investi-
gative pathway.
Alternatives to serum amylase include urinary
amylase and serum lipase. Amylase has a half-life
of 2 hours and cleared in the urine such that the
urinary amylase levels peak some 12 to 24 hours
later and so may be of beneﬁt in assessing patients
presenting in a delayed manner after the peak of
the serum amylase. Serum lipase levels rise
earlier in the course of acute pancreatitis reaching
a peak within 24 hours and a result of a longer
half-life remain elevated for 8 to 14 days.
7 As a
result, like urinary amylase, it is superior to
serum amylase in conﬁrming acute pancreatitis in
patients presenting late to the surgeon.
12 Further-
more, lipase has a greater sensitivityand speciﬁcity
(85–100% and 84.7–99%, respectively) for pancrea-
titis.
3,13 Serum lipase is in fact noted to be superior
to amylase and recommended in the BSG guide-
lines, however, the test is not routinely available
in the majority of laboratories in the UK.
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4Conclusions
Patients presenting on the surgical intakewith epi-
gastric pain and hyperamylasaemia not diagnostic
of pancreatitis should be carefully investigated in
the same way as per acute pancreatitis as gall-
stones will be present in at least half of the cases.
If ultrasound is not diagnostic then cross-sectional
imaging with CT or MRI is appropriate and in
some cases EUS. Failure to investigate pancreatitis
will also mean that these patients will miss out on
early deﬁnitive treatment and will be at risk for
further exacerbations.
It is also important, in the emergency setting, to
consider other causes of hyperamylasaemia
especially if the history is inconsistent with pan-
creatitis or gallstone disease as some conditions
may warrant urgent investigation and treatment.
In particular it is important to elicit an accurate
drug history to identify potential aetiological
agents as increasing numbers of patients are pre-
scribed medications that may induce pancreatitis.
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